Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence, clinical features, laboratory findings and outcome of patients with multiple myeloma presenting with extramedullary relapse.
Papanikolaou X, Repousis P, Tzenou T, Maltezas D, Kotsopoulou M, Megalakaki K, Angelopoulou M, Dimitrakoloulou E, Koulieris E, Bartzis V, Pangalis G, Panayotidis P, Kyrtsonis MC. Papanikolaou X, et al. Leuk Lymphoma. 2013 Jul;54(7):1459-64. doi: 10.3109/10428194.2012.746683. Epub 2012 Dec 14. Leuk Lymphoma. 2013. PMID: 23151071
The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma.
Papanikolaou X, Alapat D, Rosenthal A, Stein C, Epstein J, Owens R, Yaccoby S, Johnson S, Bailey C, Heuck C, Tian E, Joiner A, van Rhee F, Khan R, Zangari M, Jethava Y, Waheed S, Davies F, Morgan G, Barlogie B. Papanikolaou X, et al. Leukemia. 2015 Aug;29(8):1713-20. doi: 10.1038/leu.2015.65. Epub 2015 Mar 10. Leukemia. 2015. PMID: 25753926 Free PMC article.
Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set.
Ziff M, Lawson G, De-Silva D, Cheesman S, Kyriakou C, Mahmood S, Papanikolaou X, Rabin N, Sachchithananthan S, Sive J, Wechalekar A, Yong K, Popat R. Ziff M, et al. Among authors: papanikolaou x. Leuk Lymphoma. 2021 May;62(5):1243-1246. doi: 10.1080/10428194.2020.1864356. Epub 2021 Jan 13. Leuk Lymphoma. 2021. PMID: 33439062 No abstract available.
Impact of COVID-19 on peripheral blood stem cell mobilization for myeloma patients.
Camilleri M, McGrath T, Wilson W, Ings SJ, Horder J, Newrick F, Sive J, Papanikolaou X, Popat R, Kyriakou C, Yong K, Rabin N. Camilleri M, et al. Among authors: papanikolaou x. Leuk Lymphoma. 2021 Dec;62(12):3023-3026. doi: 10.1080/10428194.2021.1941930. Epub 2021 Jun 24. Leuk Lymphoma. 2021. PMID: 34162310 No abstract available.
Salvage second autologous stem cell transplant for relapsed multiple myeloma in the novel agent era benefits a subset of patients: single-center UK experience.
Richards H, Chavda SJ, Wilson W, Camilleri M, Cohen O, Horder J, Newrick F, Papanikolaou X, Sive J, Lee L, Popat R, Wechalekar A, Kyriakou C, Yong K, Rabin N. Richards H, et al. Among authors: papanikolaou x. Leuk Lymphoma. 2021 Dec;62(14):3544-3547. doi: 10.1080/10428194.2021.1961240. Epub 2021 Aug 4. Leuk Lymphoma. 2021. PMID: 34348069 No abstract available.
Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single center experience.
Nesr G, Shah R, Kyriakou C, Sive J, Popat R, Yong K, Wisniowski B, Xu K, Wechalekar A, Lee L, Ings S, Papanikolaou X, Mahmood S, Mcmillan A, Horder J, Newrick F, Marfil J, Ainley L, Asher S, Cheesman S, Rabin N. Nesr G, et al. Among authors: papanikolaou x. Leuk Lymphoma. 2023 Jul-Aug;64(8):1465-1471. doi: 10.1080/10428194.2023.2216817. Epub 2023 Jun 1. Leuk Lymphoma. 2023. PMID: 37259553 Free article.
40 results